The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro

Neuroendocrinology Letters

Volumn 26, Issue 3, 2005, Pages 205-208

  Melkersson, Kristina ^a,b   Jansson, Eva ^b  

^a Sollentuna Psychiatric Polyclinic   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic agents; In vitro; Insulin; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; INSULIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; INCUBATION TIME; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET CELL; RADIOIMMUNOASSAY; RANK SUM TEST; RAT;

EID: 22144469147     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-96.
2. Ammon HP, Orci L, Steinke J. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther 1973; 187:423-9.
3. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96.
4. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40:509-22.
5. El-Denshary ES, Montague W. Effects of drugs on glucose and tolbutamide-stimulated insulin release from isolated rat islets of Langerhans. Biochem Pharmacol 1976; 25:1451-4.
6. El-Denshary ES, Ismail NA, Montague W. Effects of chlorpromazine on isolated rat islets of Langerhans. Horm Metab Res 1977; 9:95.
7. Fenton WS. Review: most antipsychotic drugs are associated with weight gain. EBMH 2000; 3:58.
8. Herbert V, Lau K-S, Gottlieb CW, Bleicher SJ. Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 1965; 25:1375-84.
9. Hermansen K. Haloperidol, a dopaminergic antagonist: somatostatin-like inhibition of glucagon and insulin release from the isolated, perfused canine pancreas. Diabetologia 1978; 15:343-7.
10. Joost HG, Göke B, Hasselblatt A. Effects of pimozide and apomorphine on insulin secretion from the perfused rat pancreas. Arch Int Pharmacodyn 1983; 263:155-63.
11. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994; 55 [5, suppl.]:5-12.
12. Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134-41.
13. Melkersson KI, Hulting A-L, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60:783-91.
14. Melkersson K, Hulting A-L. Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology 2001; 154:205-12.
15. Melkersson K, Khan A, Hilding A, Hulting A-L. Different effects of antipsychotic drugs on insulin release in vitro. Eur Neuropsychopharmacol 2001; 11:327-32.
16. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol 2004; 14:115-9.
17. Melkersson KI, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64:701-23.
18. Nakadate T, Kubota K, Nakaki T, Kato R. Effect of chlorpromazine on insulin release in mice: comparison between in vivo and in vitro. Jpn J Pharmacol 1982; 32:950-3.
19. Olefsky JM. Insulin resistance. In: Porte D, Sherwin RS, editors. Diabetes Mellitus. Stamford, CT: Appleton and Lange; 1997. p.513-52.
20. Prakash C, Kamel A, Gummerus J, Wilner K. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 1997; 25:863-72.
21. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275:101-13.
22. Sussman KE, Pollard HB, Leitner JW, Nesher R, Adler J, Cerasi E. Differential control of insulin secretion and somatostatin-receptor recruitment in isolated pancreatic islets. Biochem J 1983; 214:225-30.
23. Sutton R, Peters M, McShane P, Gray DW, Morris PJ. Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation 1986; 42:689-91.
24. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000; 101:416-32.
25. Woods SC, Kaiyala K, Porte D, Schwartz MW. Food intake and energy balance. In: Porte D, Sherwin RS, editors. Diabetes Mellitus. Stamford, CT: Appleton and Lange; 1997. p.175-92.
26. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998; 106:475-7.